Stocks Health care GDTC
NASDAQ · Health careCytoMed Therapeutics Ltd (GDTC)
CytoMed Therapeutics Ltd reported revenue of $252.3K in fiscal 2025, up 395.9% from a year earlier. It posted a net loss of $3.1M. In fiscal 2025 capital spending exceeded operating cash flow by $3.4M. At December 31, 2025 it held $1.6M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 31, 2026.
Key facts about CytoMed Therapeutics Ltd
- Net worth
- CytoMed Therapeutics Ltd has a market value (market cap) of $9.9M at the latest share price, and shareholders' equity of $5.1M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $252.3K (+395.9% year on year), with a net loss of $3.1M.
- Cash flow
- In fiscal 2025 operations used $2.9M of cash.
- Latest report
- The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on March 31, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What CytoMed Therapeutics Ltd does
CytoMed Therapeutics Ltd is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker GDTC.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $252.3K | -$3.1M | -$0.27 | -$3.4M |
| 2024 | $50.9K | -$1.8M | -$0.16 | -$3M |
| 2023 | n/a | -$3.1M | -$0.29 | -$2.6M |
| 2022 | n/a | -$2.3M | -$0.30 | -$1.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where GDTC ranks in Health care
Latest SEC filings
What CytoMed Therapeutics Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 30, 2026
- July 24, 2026Activist stake changed SCHEDULE 13D/A
- June 23, 2026
- June 3, 2026
- May 15, 2026
- May 11, 2026
- April 14, 2026
- March 31, 2026
- March 31, 2026Annual report (foreign issuer) 20-F · period to December 31, 2025Revenue rose 396% to $252.3K versus the prior year; diluted EPS -$0.27 versus -$0.16.
- January 28, 2026
Insider trades
What the people running CytoMed Therapeutics Ltd did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 20, 2026 | Choo Chee KongDirector, 10% owner | Bought | 100,000 | $150K |
| July 14, 2026 | Choo Chee KongDirector, 10% owner | Bought | 100,000 | $150K |
| May 13, 2026 | Choo Chee KongDirector, 10% owner | Bought | 112,000 | $128.8K |
Who owns GDTC
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Choo Chee Kong13D, may seek influence | 24.3% | July 24, 2026 |
| mDR LTD13G, passive | 11.33% | March 24, 2025 |
| 28 Consultants Ltd13G, passive | 7.62% | March 4, 2025 |
Largest institutional holders
Insiders
1 insiders reported holding 1,060,648 shares in total, about $886.6K at the last price.
| Holder | Shares |
|---|---|
| Choo Chee KongDirector, 10% owner | 1,060,648 |
Questions about GDTC
What does CytoMed Therapeutics Ltd do?
CytoMed Therapeutics Ltd is a company in the Health care sector, listed on NASDAQ as GDTC. Its shares trade on NASDAQ under the ticker GDTC.
What is CytoMed Therapeutics Ltd's net worth?
CytoMed Therapeutics Ltd has a market value (market cap) of $9.9M at the latest share price, and shareholders' equity of $5.1M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is CytoMed Therapeutics Ltd profitable?
No. In fiscal 2025 it reported a net loss of $3.1M on revenue of $252.3K.
How much revenue does CytoMed Therapeutics Ltd make?
In fiscal 2025 CytoMed Therapeutics Ltd reported revenue of $252.3K. That is 395.9% more than a year earlier.
When did CytoMed Therapeutics Ltd last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 31, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from September 30, 2026.
Similar companies
Compare GDTC with
Follow GDTC
Get an email when CytoMed Therapeutics Ltd files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values CytoMed Therapeutics Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.